Seres therapeutics reports ser-155 phase 1b cohort 1 results showing successful drug bacteria engraftment and substantial reduction in pathogen domination in the gastrointestinal microbiome

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported initial clinical data about ser-155. ser-155 is an oral, cultivated bacterial consortia investigational therapeutic designed to prevent enteric-derived infections and resulting blood stream infections, as well as induce immune tolerance responses to reduce the incidence of graft-versus-host disease (gvhd) in patients undergoing allogeneic hematopoietic stem cell.
MCRB Ratings Summary
MCRB Quant Ranking